Plain-English translation of NCT03933631 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
Glaucoma is a serious eye condition where pressure builds up and damages your optic nerve, potentially leading to blindness. This trial is testing whether , an eye drop medication, helps protect the success of a newer glaucoma surgery called Kahook goniotomy (often done together with cataract surgery). The medication is thought to help keep the surgical opening from closing up after the procedure, but doctors have never actually proven whether this medication truly helps.
After goniotomy surgery, doctors worry that scar tissue might close the new pathway created for fluid to drain from the eye, which would cause the surgery to fail. This medication is traditionally given to prevent that scarring, but there is no solid scientific evidence that it actually works—so this trial is designed to find out for sure.
You likely qualify if…
You likely don't qualify if…
You will receive cataract and glaucoma surgery at Montefiore Medical Center. After surgery, you will be randomly assigned to either use the study eye drops in addition to standard post-operative drops for one month, or to use only the standard drops without the additional medication. You will need to follow up with your eye doctor as scheduled to monitor how well the surgery is working and watch for any side effects.
AI-generated summary from trial data · Jun 6, 2026 · Not medical advice
United States
Phase
Large-scale testing
Sponsor
Montefiore Medical Center
Enrollment target
~142 participants
Started
May 2019
Primary completion
June 2028
Age range
30 Years – 100 Years
Last updated on clinicaltrials.gov in November 2025.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Wen-Jeng (Melissa) Yao, MD
Montefiore Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.